THE 60 GY IN 3 TO 5 FRACTIONS RECOMMENDATION FOR STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR STAGE I NON-SMALL CELL LUNG CANCER (NSCLC) IS OVERKILL: A PLEA FOR A INDIVIDUALISED DOSE PRESCRIPTION

被引：0
|
作者：
De Ruysscher, D. [1 ]
van Baardwijk, A. [2 ]
Tome, W. [3 ]
Bentzen, S. [3 ]
Wanders, S. [2 ]
Reymen, B. [2 ]
Borger, J. [2 ]
van Elmpt, W. [2 ]
Ollers, M. [2 ]
Lambin, P. [2 ]
机构：
[1] MUCM, Maastricht, Netherlands
[2] MAASTRO Clin, Maastricht, Netherlands
[3] Univ Wisconsin, Sch Med & Publ H, Madison, WI USA
来源：
RADIOTHERAPY AND ONCOLOGY | 2010年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1044
引用
收藏
页码：S356 / S357
页数：2
相关论文
共 50 条
  • [11] Stereotactic body radiotherapy for stage I non-small cell lung cancer
    Slotman, Ben J.
    JOURNAL OF RADIOSURGERY AND SBRT, 2011, 1 (01): : 63 - 69
  • [12] Selection of patients for stereotactic lung radiotherapy (SBRT) for early stage non-small cell lung cancer (NSCLC)
    Pearson, S.
    Franks, K.
    Pearson, S.
    Purdie, T.
    Bissonnette, JI-P.
    Cho, J.
    Sun, A.
    Kane, G.
    Payne, D.
    Bezjak, A.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S51 - S52
  • [13] Is stereotactic body radiotherapy (SBRT) safe for central non-small cell lung cancer (NSCLC) lesions?
    Patel, A. H.
    Ajlouni, M.
    Jin, J.
    Lu, M.
    Ryu, S.
    Movsas, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S434 - S435
  • [14] The Effect of Stereotactic Body Radiotherapy (SBRT) Dose-Fraction (fx) Schema on Non-Small Cell Lung Cancer (NSCLC)
    Pirlamarla, M. K.
    Deng, M.
    Yankey, H. N.
    Dougherty, T.
    Handorf, E.
    Kumar, S. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E49 - E49
  • [15] Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer
    Yang, Dan
    Cui, Jianing
    Zhao, Jun
    You, Jing
    Yu, Rong
    Yu, Huiming
    Jiang, Leilei
    Li, Dongming
    Xu, Bo
    Shi, Anhui
    THORACIC CANCER, 2020, 11 (03) : 754 - 761
  • [16] Hypofractionated (62.5 gy/5 fx) stereotactic body radiotherapy for stage IA non-small cell lung cancer
    Gonn, K.
    Kozuka, T.
    Kumada, M.
    Nemoto, K.
    Nose, T.
    Oguchi, M.
    Yamashita, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S486 - S486
  • [17] Stereotactic fractionated radiotherapy (SRT) of non-small cell lung cancer (NSCLC) stage I
    Zimmermann, F
    Geinitz, H
    Schill, S
    Branislav, J
    Molls, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S533 - S533
  • [18] LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located Non-small Cell Lung Cancer (NSCLC)
    Faivre-Finn, C.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E65 - E65
  • [19] Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC).
    Senan, S.
    Gundy, C.
    Haasbeek, C. J.
    Slotman, B. J.
    Aaronson, N. K.
    Lagerwaard, F. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [20] Clinical Outcomes and Toxicity after Stereotactic Body Radiotherapy (SBRT) with or without Adjuvant Chemotherapy for Stage I Non-Small Cell Lung Cancer (NSCLC)
    Vance, S.
    Ye, H.
    Baschnagel, A.
    Mangona, V.
    Yan, D.
    Grills, I.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S292 - S293
12345